Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067015 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT00067015: Completed Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00067015 is a Phase 3 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00067015, a Phase 3 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue and may improve quality of life and help patients live more comfortably. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin and bicalutamide may fight cancer by stopping the production of androgens. It is not yet known whether radiation therapy is more effective with or without goserelin and bicalutamide in treating prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of high-dose radiation therapy with or without bicalutamide and goserelin in treating patients who have prostate cancer.
Interventions
- PROCEDURE quality-of-life assessment
- RADIATION radiation therapy
- DRUG goserelin acetate
- DRUG bicalutamide
- PROCEDURE assessment of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2003-05 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067015
The ClinicalTrials.gov registry entry for NCT00067015 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which quality-of-life assessment is the first listed.
NCT00067015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067015 about?
NCT00067015 is a clinical study titled "Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue and may improve quality of life and help patients live more comfortably. Androgens can stimulate the growth of prostate cancer cells. Drugs su...
What is the current status of trial NCT00067015?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2003-05. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00067015?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), radiation therapy (RADIATION), goserelin acetate (DRUG), bicalutamide (DRUG), assessment of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00067015?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.